Status:
COMPLETED
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures
Lead Sponsor:
Pfizer
Conditions:
Seizure Disorder, Partial
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.
Eligibility Criteria
Inclusion
- Must have met the inclusion criteria for the preceding double-blind study
- Have received double-blind study medication and wish to receive open-label pregabalin.
Exclusion
- Cannot have absence seizures.
Key Trial Info
Start Date :
July 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
455 Patients enrolled
Trial Details
Trial ID
NCT00141388
Start Date
July 1 1998
End Date
October 1 2005
Last Update
November 6 2009
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35249
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35255
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-0021
4
Pfizer Investigational Site
Phoenix, Arizona, United States, 85006